Yingli Pharma brings small molecule research to the US in new pact with MD Anderson; UCB's psoriatic arthritis drug shows positive PhIII results
Shanghai biotech Yingli Pharma wants to bring its small molecule drug research global — and a new pact with MD Anderson will …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
